3 things to expect from CSL (ASX:CSL) over the next decade

From manufacturing to dividends, CSL Limited (ASX:CSL) has big plans in the pipeline for the next 10 years. Here are some of its plans.

| More on:
a doctor looking up at question marks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you find yourself worrying about the fact the CSL Limited (ASX: CSL) share price has fallen 15% in the last 12 months, here's a great way to shift your focus.

Think about how the company might look a decade from now. Yes, ten whole years.

After all, the real magic of investing is finding companies that can relentlessly grow and compound earnings over long periods of time. Thinking about a company's long-term plans can help to put short-term share price movements in perspective.

And CSL actually has a strong vision for how it wants to grow over the next decade. Here are three things we can expect to see from the company over the next ten years:

1. A new manufacturing facility in Australia

In November last year, CSL announced that the company's wholly-owned subsidiary Seqirus will invest more than $800 million in a new manufacturing facility in Melbourne. The facility will produce seasonal and pandemic flu vaccines as well as antivenoms for Australian snakes, spiders and marine creatures.

The new facility is supported by a 10-year supply agreement with the Australian Government and is expected to be operational by mid-2026.

2. Significant investment in R&D

In addition to the new manufacturing facility, CSL has announced some significant plans to continue investing in research and development (R&D). This includes building a brand-new global headquarters in the Parkville Biomedical Precinct in Melbourne. The huge 16-storey building is expected to open in 2024 and will accommodate 800 employees and "expand our R&D footprint" according to CSL.

The company is also undertaking the construction of a special R&D campus in Marburg, Germany which is scheduled for completion in 2022 and will have enough space for around 600 employees.

Innovation is a core principle of CSL's business so investing in R&D is an important driver of future growth. In FY20, CSL invested an incredible US$922 million in R&D across its businesses and expects to invest up to 11% of revenue on R&D in FY21.

3. More digitalisation across the business

One of the core pillars of CSL's strategy over the coming decade is a focus on a digital transformation. Digital investments are often hard to see from the outside of a company. However, digital tools will help with essential areas like improving quality control, supply chain efficiency and regulatory compliance.

For example, the introduction of automated inspection technology can increase the number of vials inspected every minute which means manufacturing operations can accommodate greater demand.

Regan Pearson has no position in any of the stocks mentioned. You can follow him on Twitter @Regan_Invests. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Blue Chip Shares

Blue Chip Shares

These super-strong ASX 200 blue chip shares could deliver 20% returns

Analysts believe big returns could be on the cards for owners of these shares.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

ASX blue chip shares: The best of the best for February 2024

These top stocks are strong buys according to analysts.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Blue Chip Shares

Buy these top ASX 200 stocks for 18%+ returns

Analysts are tipping these shares to rise strongly from current levels.

Read more »

positive asx share price represented by lots of hands all making thumbs up gesture
Blue Chip Shares

Morgans says these ASX 50 shares are strong buys

These big-name stocks are buys this month according to the broker.

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Blue Chip Shares

Why Goldman Sachs rates these ASX 200 shares as buys

Here's what the broker is saying about these top stocks.

Read more »

Man smiling at a laptop because of a rising share price.
Blue Chip Shares

3 top ASX 200 blue chip shares to buy in February

Analysts see big returns on offer from these buy-rated shares.

Read more »

Person holding blue chips.
Blue Chip Shares

3 ASX blue-chip stocks I think every Aussie should own

Every Aussie investor should consider adding these three ASX blue-chip stocks to their investment portfolio.

Read more »

world's biggest companies represented by one person holding cityscape and another holding earth in hands
Blue Chip Shares

2 world-class ASX 50 shares to buy for your portfolio

Analysts are saying good things about these

Read more »